Obesity and malnutrition similarly alter the renin–angiotensin system and inflammation in mice and human adipose

Pinheiro, Thales de Almeida; Barcala-Jorge, Antônio Sérgio; Andrade, João Marcus Oliveira; Pinheiro, Thaisa de Almeida; Ferreira, Emíllio César Neves; Crespo, Thaísa Soares; Batista-Jorge, Gislaine Cândida; Vieira, Cássio André; Lelis, Deborah de Farias; Paraíso, Alanna Fernandes; Pinheiro, Ugo Borges; Bertagnolli, Mariane; Albuquerque, Carlos Juliano Brant; Guimarães, André Luiz Sena; Paula, Alfredo Maurício Batista de; Caldeira, Antônio Prates; Santos, Sérgio Henrique Sousa

doi:10.1016/j.jnutbio.2017.06.008

Cited by 87 publications

(74 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Drugs that inhibit the renin–angiotensin system, alone or together with inhibitors of neprilysin (sacubitril/valsartan), can prevent the progression of chronic kidney disease in patients with type 2 diabetes; however, they may also have salutary effects on epicardial adipose tissue. Angiotensin II contributes to the genesis of inflammation in adipose tissue in metabolic disorders . In obesity, adipocytes are a major source of the body's production of angiotensinogen, and bariatric surgery attenuates the activation of the renin–angiotensin system .…”

Section: Therapeutic Challenges In Patients With a Metabolic Disordermentioning

confidence: 99%

“…Angiotensin II contributes to the genesis of inflammation in adipose tissue in metabolic disorders. 118,119 In obesity, adipocytes are a major source of the body's production of angiotensinogen, 12 and bariatric surgery attenuates the activation of the renin-angiotensin system. 120 Furthermore, imbalances in the control of the renin-angiotensin system cause inflammation and dysfunction of epicardial fat, 121,122 and angiotensin II stimulates the release of proinflammatory adipocytokines.…”

Section: Inhibitors Of the Renin-angiotensin System And Neprilysinmentioning

confidence: 99%

See 1 more Smart Citation

Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment

Packer

2019

European J of Heart Fail

View full text Add to dashboard Cite

Obesity and diabetes can lead to heart failure with preserved ejection fraction (HFpEF), potentially because they both cause expansion and inflammation of epicardial adipose tissue and thus lead to microvascular dysfunction and fibrosis of the underlying left ventricle. The same process also causes an atrial myopathy, which is clinically evident as atrial fibrillation (AF); thus, AF may be the first manifestation of HFpEF. Many patients with apparently isolated AF have latent HFpEF or subsequently develop HFpEF. Most patients with obesity or diabetes who have AF and exercise intolerance have increased left atrial pressures at rest or during exercise, even in the absence of diagnosed HFpEF. Among patients with AF, those who also have latent HFpEF have increased risk for systemic thromboembolism and death. The identification of HFpEF in patients with obesity or diabetes alters the risk‐to‐benefit relationship of commonly prescribed treatments. Bariatric surgery and statins can ameliorate AF and reduce the risk for HFpEF. Conversely, antihyperglycaemic drugs that promote adipogenesis or cause sodium retention (insulin and thiazolidinediones) may increase the risk for heart failure in patients with an underlying ventricular myopathy. Patients with obesity and diabetes who undergo catheter ablation for AF are at increased risk for AF recurrence and for post‐ablation increases in pulmonary venous pressures and worsening heart failure, especially if HFpEF coexists. Therefore, AF may be the earliest indicator of HFpEF in patients with obesity or type 2 diabetes, and recognition of HFpEF alters the management of these patients.

show abstract

Section: Therapeutic Challenges In Patients With a Metabolic Disordermentioning

confidence: 99%

Section: Inhibitors Of the Renin-angiotensin System And Neprilysinmentioning

confidence: 99%

Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment

Packer

2019

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…This is an important finding because adipose tissue might also be vulnerable to COVID‐19. It should be noted, however, that there was no difference in the expression of ACE2 protein by adipocytes and adipose progenitor cells between individuals with obesity and those without 10 . However, individuals with obesity have more adipose tissue and therefore an increased number of ACE2‐expressing cells and consequently a larger amount of ACE2 9 .…”

mentioning

confidence: 92%

Risk of COVID‐19 for patients with obesity

2020

View full text Add to dashboard Cite

“…Indeed, the increased expression of some RAS components has been associated with CVDs and obesity (7). The gene expression of RAS components is increased in the visceral adipose tissue of obese humans (8); the production of angiotensin II (AngII) also increases with obesity (7). This peptide stimulates the proliferation of the vascular smooth muscle and induces cardiomyocyte hypertrophy, endothelium dysfunction and vasoconstriction, which all lead to cardiac and vascular remodeling (9).…”

Section: Introductionmentioning

confidence: 99%

Polymorphisms of the renin-angiotensin system are not associated with overweight and obesity in a general adult population

Lelis

Pereira

Mill

et al. 2019

Archives of Endocrinology and Metabolism

Self Cite

View full text Add to dashboard Cite

Objective:The increased prevalence of obesity and associated comorbidities, such as cardiovascular and metabolic diseases, has gained attention worldwide, and the renin-angiotensin system (RAS) has been pointed out as a possible link. Thus, the present study aimed to verify the possible association between angiotensinogen (AGT) or angiotensin-converting enzyme (ACE) polymorphisms with overweight and obesity in adults. Subjects and methods: The present investigation was a population-based cross-sectional study including 1,567 individuals from an urban area in Brazil. Anthropometric, clinical and biochemical parameters were evaluated, and all individuals were genotyped for the ACE I/D and AGT M/T polymorphisms. Results: The prevalence of overweight was higher among men, whereas obesity was more prevalent among women. However, the frequency of ACE or AGT polymorphisms was similar among body mass index (BMI) categories. In addition, the mean age-adjusted BMI averages did not change significantly for ACE or AGT polymorphisms, regardless of sex or BMI category. The age-adjusted BMI average for the combination of ACE and AGT genotypes evidenced no significant differences regardless of sex or BMI categories. Results were similar when BMI was replaced by waist circumference (WC). Conclusions: We were not able to find any associations between BMI and WC (overweight/obesity) and ACE and AGT polymorphisms, indicating that the RAS system might not be involved in overweight and obesity, at least based on genetic backgrounds. However, further studies must measure RAS components to elucidate this question.

show abstract

Obesity and malnutrition similarly alter the renin–angiotensin system and inflammation in mice and human adipose

Cited by 87 publications

References 44 publications

Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment

Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment

Risk of COVID‐19 for patients with obesity

Polymorphisms of the renin-angiotensin system are not associated with overweight and obesity in a general adult population

Contact Info

Product

Resources

About